CJC-1295 (No DAC) + Ipamorelin

First: what exactly is in the combination?

Products marketed as CJC-1295 No DAC, CJC-1295 without DAC, Modified GRF 1-29, Mod GRF (1-29), or tetrasubstituted GRF (1-29) generally refer to a 29-amino-acid GHRH analog. FDA calls the corresponding active moiety CJC-1295 free base (and discusses its acetate salt). It is chemically different from albumin-binding CJC-1295 DAC.

Ipamorelin is a five-amino-acid GH secretagogue acting through GHS-R1a. The two peptides approach pituitary GH release through different signaling systems, which explains interest in combining them.

Confirm No DAC / Modified GRF 1-29. DAC-containing CJC-1295 uses different evidence and cannot be substituted.

Product-label rule: A label saying only “CJC-1295 + ipamorelin” is incomplete. It should state whether CJC-1295 contains the MPA-Lys/DAC group, the quantity of each peptide, the salt/counterion, and the analytical identity. A “10 mg blend” might mean 5 mg + 5 mg, not 10 mg of each.

Is there an FDA-approved dosage?

No. Neither component has an FDA-approved product or dosage, and the fixed combination has never been approved.

FDA’s 2024 evaluation found no peer-reviewed nonclinical or clinical data establishing the safety or effectiveness of CJC-1295 free base or acetate, and raised characterization, impurity, aggregation, solubility, and immunogenicity concerns for an injectable compounded peptide.

FDA separately lists ipamorelin acetate among bulk substances that may present significant safety risks in compounding, citing aggregation and impurities, characterization challenges, serious events in an IV clinical study, and no identified safety information for the proposed subcutaneous route.

There is currently no FDA-approved dosage for CJC-1295 (No DAC) plus ipamorelin. The amounts below describe formal research involving the individual components or anecdotal combination protocols—not an established prescribing regimen.

Has the exact combination been studied in humans?

No controlled human trial of the exact combination was identified. This creates more than an efficacy gap: there is no validated combined PK profile, dose-response curve, ratio comparison, route comparison, escalation schedule, treatment duration, or adverse-event rate.

Reports of seized or unapproved peptide products containing Modified GRF 1-29 and ipamorelin confirm the pairing exists in the illicit performance-enhancement market, but chemical detection is not evidence of dosing, efficacy, or safety.

Human clinical research on the individual components

Keep the ipamorelin IV clinical table visually and conceptually separate from any subcutaneous combination protocol table. IV weight-based acute or postoperative exposures do not validate fixed SC microgram blends.

The single-dose ipamorelin study found dose-proportional PK, an approximately two-hour terminal half-life, and a brief GH response peaking around 0.67 hour. The postoperative trial did not meet its primary or secondary efficacy endpoints. These studies establish that IV ipamorelin can produce a GH response; they do not validate fixed 100–300 mcg subcutaneous doses, long cycles, or combination use.

The familiar CJC-1295 trial used the long-acting DAC molecule at 20–250 mcg/kg in single and repeat SC studies. Those data cannot be repurposed as evidence for a short-acting no-DAC peptide or for pairing it with ipamorelin.

Why the combination is thought to be synergistic

The biological rationale is stronger than the dosage evidence. A GHRH analog activates GHRH receptors on somatotrophs; ipamorelin activates GHS-R1a. Stimulating complementary pathways can produce a larger GH pulse than either pathway alone.

Human evidence supports this class-level concept, but with other molecules: IV GHRH + GHRP-6, and GHRH + hexarelin (including low-dose hexarelin potentiation). Those studies did not use Modified GRF 1-29 or ipamorelin and cannot validate a modern combination protocol.

CJC-1295 No DAC + ipamorelin research dosage

Searches for this combination most often lead to clinic, vendor, community, and protocol pages. Consistency makes the conventions worth documenting, but repetition is not independent clinical validation.

No controlled human trial of the exact combination was identified. Component research supports only that IV ipamorelin can produce dose-related GH release and that GHRH/GHRP pathway co-stimulation can be synergistic with other agents.

The total mass is not a pharmacologically interchangeable “combined dose.” The two peptides have different molecular weights, receptors, and unknown subcutaneous exposure.

Reported combination research dosage range

This range describes the online protocol landscape, not an established safe or effective interval. It should not be converted into weight-based instructions or a “maximum dose.” No reconstitution or injection calculator is provided—no validated target dose exists.

Anecdotal versus clinically studied dosing

The lack of clinical overlap is complete. Published ipamorelin trials used IV, weight-based dosing in acute research or hospitalized postoperative populations. The online combination uses fixed subcutaneous amounts over months. Neither route conversion nor safety can be inferred without bioavailability and interaction data.

Research protocol variations

1. 1:1 versus 1:2 versus 1:3 ratios. Equal-mass blends commonly produce 1:1 because they are convenient. Separate vials make 1:2 or 1:3 easier to report. No clinical comparison established any ratio; more ipamorelin than Modified GRF 1-29 is a community convention.
2. Once daily versus multiple daily administrations. Bedtime-only vs repeated-pulse strategies have not been compared for the exact combination. A two-hour IV half-life for ipamorelin does not establish the ideal SC interval; Modified GRF 1-29 human PK is unresolved.
3. Daily versus five days on / two days off. No exact-combination trial evaluated desensitization or showed that two off-days improve response or safety.
4. Fixed blend versus separate components. Blends lock ratio and complicate analytics; separate vials add quality variables. No study shows either presentation is better. Blends also make adverse-effect attribution harder.

Timing, fasting, and “pulse” claims

Bedtime, fasted, pre-meal, and post-training schedules are frequently promoted based on physiology hypotheses (glucose/FFA blunting GH; avoiding competition with a natural pulse). Those are not results from a Modified GRF 1-29 plus ipamorelin trial.

The exact combination has not been compared at bedtime versus morning; fasted versus fed; once daily versus divided daily; before versus after exercise; or continuously versus cyclically. It is inappropriate to label any timing schedule “optimal.”

Why these research amounts are repeated

1. The 100 mcg “saturation” story — unverified; no exact-molecule occupancy study; 1 mcg/kg → 100 mcg only at 100 kg.
2. Complementary-receptor rationale — strongest scientific rationale is acute GHRH/GHRP synergy with other molecules; mechanism does not identify a dose.
3. Vial arithmetic and fixed-ratio blends — equal 5 mg/5 mg blends encourage equal-mass descriptions; commercial convenience ≠ biological optimum.
4. Half-life assumptions — IV ipamorelin ~2 h plus unverified ~30 min Mod GRF figure cannot generate a validated SC coadministration frequency.

Dosage evidence ladder

Make the absence of an exact-combination human protocol—not the apparent precision of 100/200 mcg shorthand—the central finding.

Is there a research escalation schedule?

No formal escalation schedule exists. Human ipamorelin studies assigned weight-based IV arms; they did not titrate a subcutaneous combination. FDA identified no exact clinical dosing for Modified GRF 1-29.

Online sources sometimes describe beginning with 100/100 mcg and then increasing ipamorelin to 200 or 300 mcg, or increasing from once to twice daily. This is an anecdotal pattern, not evidence-based titration. No study shows that escalating one component is safer than increasing frequency, that response plateaus at a particular amount, or that biomarkers make such escalation safe.

Preclinical research dosage

No reproducible animal dosing study of the exact Modified GRF 1-29 plus ipamorelin combination was identified in the FDA reviews or the primary literature searches used for this page. Individual-component and other GHRH/GHRP combination experiments cannot be presented as exact-combination evidence.

Animal doses should not be converted casually into human doses. Species differences in GH pulsatility, receptor pharmacology, metabolism, and body-surface scaling make simple mcg/kg conversion misleading.

Safety and adverse effects

Exact-combination safety is unknown: there is no trial from which to calculate adverse-effect incidence for chronic subcutaneous combined use.

Extra caution is warranted with active malignancy, pituitary disease, abnormal IGF-1, diabetes or impaired glucose control, pregnancy or breastfeeding, proliferative retinopathy, significant edema, or untreated sleep apnea. Because no approved protocol exists, decisions about endocrine testing or exposure require a licensed clinician.

Anti-doping status

Growth-hormone-releasing factors and growth-hormone secretagogues are prohibited under the WADA Prohibited List. Athletes subject to anti-doping rules should not assume that “research peptide,” compounded status, or an online clinic prescription makes the combination permissible. Product contamination or mislabeling adds further risk.

Bottom line

CJC-1295 (No DAC) plus ipamorelin is a mechanistically plausible but clinically unvalidated pairing. Acute human research with other GHRH/GHRP combinations supports the possibility of synergistic GH release; it does not establish the marketed combination’s dose, ratio, timing, outcomes, or safety.

The most repeated online convention—about 100 mcg Modified GRF 1-29 plus 100–300 mcg ipamorelin, once to three times daily by subcutaneous injection for 8–16 weeks—should be labeled anecdotal research protocol. There is no FDA-approved dose, no exact-combination human dose range, no validated titration, and no established maximum.

No controlled human trial of the exact combination was identified. Preserve that finding near the top, beside the research range, and in the FAQ.

Frequently asked questions

Primary and regulatory references

• FDA

  CJC-1295-related bulk drug substances: scientific review

  2024.

• FDA

  Ipamorelin acetate: scientific review

  2024.

• FDA

  Bulk drug substances that may present significant compounding safety risks

  Compounding safety page.

• Gobburu JVS et al.

  Pharmacokinetic-pharmacodynamic modeling of ipamorelin

  1999.

• Beck DE et al.

  Ipamorelin for postoperative ileus after bowel resection

  2014.

• ClinicalTrials.gov

  NCT01280344

  Phase 2 ipamorelin dose finding.

• Teichman SL et al.

  Prolonged GH and IGF-1 stimulation by CJC-1295 DAC

  2006 — DAC molecule, not this pairing.

• Adjacent synergy

  GHRH plus GHRP-6 in young and late adulthood

  Class-level acute synergy only.

• Adjacent synergy

  GHRH plus hexarelin in healthy controls and type 1 diabetes

  Not Modified GRF 1-29 + ipamorelin.

• Adjacent synergy

  Low-dose hexarelin plus GHRH

  Acute potentiation; different molecules.

• Raun K et al.

  Ipamorelin, the first selective growth hormone secretagogue

  1998 — foundational pharmacology; not the marketed combo.

• Thomas A et al.

  Detection of growth-hormone-releasing peptides in seized products

  2019 — detection ≠ dosing evidence.